Dihydropyrimidine Dehydrogenase (DPD) is a pyrimidine catabolic enzyme that catalyzes the two-electron reduction of pyrimidine bases uracil and thymine. Dihydropyrimidine dehydrogenase catalyzes the first step of pyrimidine catabolism by promoting the reduction of the 5,6-vinylic bond of thymine or uracil with electrons acquired from NADPH. Mammalian Dihydropyrimidine dehydrogenase is a functional homodimer and each subunit contains an FAD, an FMN and four Fe4S4 centers with two Fe4S4 centers from each subunit forming an electron transfer conduit that link the flavins within each subunit. Dihydropyrimidine dehydrogenase accepts the pervasive chemotherapeutic 5-Fluorouracil as a substrate, severely shortening its pharmacological half-life and dictating the use of elaborate compensatory administration protocols to achieve efficacious toxicity[1].
5-Iodouracil(Compound 4b)是一种不可逆的二氢嘧啶脱氢酶(DPD)抑制剂(IC50=0.22 μM),有望用于非小细胞肺癌(NSCLC)等DPD过表达实体瘤的研究。
DFP-11207 是一种具有口服活性的氟嘧啶类细胞毒性试剂,它将 5-FU 前药与可逆的 DPD 抑制剂及强效的 OPRT 抑制剂相结合,从而增强 5-FU 的药理活性,同时降低胃肠道毒性和骨髓抑制毒性,可用于癌症研究。
Gimeracil-13C3 (Gimestat-13C3) 是 13C 标记的 Gimeracil (MS-Z92589),而 Gimeracil 是口服氟嘧啶衍生物 S-1 的成分,可抑制 DNA DSB 的修复,同时也是 13C 标记的 DPYD(二氢嘧啶脱氢酶,DPD)的有效抑制剂。
Gimeracil (Standard) 是 Gimeracil 的分析标准品,用于研究及分析应用,而 Gimeracil 是口服氟嘧啶衍生物 S-1 的成分,可抑制 DNA DSB 的修复,并是 DPYD(二氢嘧啶脱氢酶,DPD)的有效抑制剂。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号